Search Results

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces the results of the Annul General Meeting.

Medigene AG announced that the Company has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor technology, which contains a control mechanism to regulate efficacy and improve safety of its T cell receptor engineered T cell therapies.

Medigene AG will present virtually at the 7th Cell and Gene Therapy In-Depth Focus Summit taking place from June 27-28, 2024, in Beijing, China.

Medigene AG will present a poster at the 21th Association for Cancer Immunotherapy Annual Meeting taking place May 15-17, 2024, in Mainz, as well as at the Healthcare House Call Virtual Conference hosted by The Benchmark Company on May 21 and 22, 2024.

Medigene AG will present at the 7th CAR-TCR Summit Europe taking place February 27-29, 2024, in London as well as at the East-West Biopharma Summit to be held March 4-6, 2024, in Singapore.

Medigene AG reported financial results for the fiscal year ended December 31, 2023, and provided a corporate update.

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, reported financial results for the first quarter of 2024.

Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard) announces today that it has selected its lead candidate for MDG2021, a T cell receptor engineered T cell (TCR-T) therapy targeting Kirsten rat sarcoma viral oncogene homologue (KRAS) G12D with human leukocyte antigen (HLA)-A*11 being developed in combination with the Company’s PD1-41BB costimulatory switch protein (CSP) technology.